Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms, and the treatment and management of high-risk MDS remains a challenge. With only two agents currently approved by the FDA and available to patients with high-risk disease, several experts agree that novel therapeutic strategies should be explored. Many ongoing clinical trials are evaluating the safety and efficacy of combination therapies, with the aim of providing more hope for patients and overcoming challenges in the field.

In this exclusive podcast, you will hear from leading experts Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Justin Taylor, MD, Sylvester Comprehensive Cancer Center, Miami, FL, who discuss the current state of the art in high-risk MDS, unmet needs, and future therapeutic approaches. 

The MDS Podcasts on VJHemOnc are supported by Gilead Oncology. Gilead Oncology has no influence over the production of the content.